Academic Journals Database
Disseminating quality controlled scientific knowledge

Polymorphisms of arylamine N-acetyltransferase2 and risk of lung and colorectal cancer

Author(s): Amjad Mahasneh | Amal Jubaili | Ahmed El Bateiha | Mohammad Al-Ghazo | Ismail Matalka | Mousa Malkawi

Journal: Genetics and Molecular Biology
ISSN 1415-4757

Volume: 35;
Issue: 4;
Start page: 725;
Date: 2012;
Original page

Keywords: NAT2 | lung cancer | colorectal cancer | polymorphisms

The arylamine N-acetyltransferase 2 (NAT2) enzymes detoxify a wide range of naturally occurring xenobiotics including carcinogens and drugs. Point mutations in the NAT2 gene result in the variant alleles M1 (NAT2 *5A), M2 (NAT2*6A), M3 (NAT2*7) and M4 (NAT2 *14A) from the wild-type WT (NAT2 *4) allele. The current study was aimed at screening genetic polymorphisms of NAT2 gene in 49 lung cancer patients, 54 colorectal cancer patients and 99 cancer-free controls, using PCR-RFLP. There were significant differences in allele frequencies between lung cancer patients and controls in the WT, M2 and M3 alleles (p < 0.05). However, only M2 and M3 allele frequencies were different between colorectal cancer patients and controls (p < 0.05). There was a marginal significant difference in the distribution of rapid and slow acetylator genotypes between lung cancer patients and controls (p = 0.06 and p = 0.05, respectively), but not between colorectal cancer patients and controls (p = 1.0 and p = 0.95, respectively). Risk of lung cancer development was found to be lower in slow acetylators [odds ratio (OR): 0.51, 95% confidence interval (95% CI): 0.25, 1.02, p-value = 0.07]. No effect was observed in case of colorectal cancer. Our results showed that NAT2 genotypes and phenotypes might be involved in lung cancer but not colorectal cancer susceptibility in Jordan.

Tango Jona
Tangokurs Rapperswil-Jona

RPA Switzerland

Robotic Process Automation Switzerland